PASTEUR Act re-introduced and levels up antimicrobial economics for strong innovation!

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter),

Woot, woot! Woot, woot! US Senators Michael Bennet (D-Colo.) and Todd Young (R-Ind.) and Representatives Mike Doyle (D-Pa.) and Drew Ferguson (R-Ga.) have today reintroduced the PASTEUR (Pioneering Antimicrobial Subscriptions to End Up surging Resistance) Act!

Here are the links you need:

As a brief review, PASTEUR was initially introduced during the last session of Congress (30 Sep 2020 newsletter) with the goal of getting feedback on the idea and generating initial support. With advice and comments taken on board, it is now being introduced in this session of Congress with the intent of getting it passed. In addition to the bicameral (Senate and House), bipartisan (Republican and Democratic) support implied by the co-sponsors, please also check the press release for statements of support from Industry, academia (Infectious Diseases Society of America), and even the UK (Thank you, Dame Sally!). We expect this to be just the beginning: already additional endorsements can be seem from groups like the Cystic Fibrosis Foundation (CF patients suffer from dangerous lung infections).


To summarize the essence of the Act (text from the one-pager, emphasis added), PASTEUR would:

  • “Form a Committee on Critical Need Antimicrobials, consisting [entirely] of representatives from relevant federal agencies, as well as [an Advisory Group of] doctors, patients, and outside experts, to develop and implement necessary guidance regarding infections of concern, and the favored characteristics [essentially, a TPP or Target Product Profile] of potential treatments.
  • “Establish a Subscription Model to encourage innovative antimicrobial drug development aimed at treating drug-resistant infections. This model will be delinked, meaning that participating developers would not receive income, as a part of their subscription payments, based on volume or quantity of sales.
  • “Terms & Conditions of the subscription contracts would include product availability to individuals on a government health insurance plan, supporting appropriate use, and completion of post market studies. These contracts could be valuated between $750 million and $3 billion.
  • “Build on Existing Frameworks to improve appropriate use through the CDC National Healthcare Safety Network and other programs to collect and report on antibiotic use and resistance data.
  • “Include Transition Measures such as smaller subscription contracts [a total of $1B is set aside for this purpose] to support novel antimicrobial drug developers that need a financial lifeline.”

Stated with a bit more detail: 

  1. A Committee of federal HHS officials, with advice from an external Advisory Group, will create a scoring scheme for new antimicrobials based on favored characteristics such as novelty, spectrum, infection(s) treated, etc.  Think of this as elements of a target product profile (TPP).
    • It will take about a year after passage and establishment of the Committee for the scoring system to emerge, but we’d expect it to have features similar to those in the NHS pilot — for details on this, see our 29 Mar 2020 newsletter and search for “point system”.  The scoring system will be issued as a proposed HHS regulation, with opportunity for everyone to give comments.
  2. That system will define the value that could be earned by a product and developers can request in advance an estimate of the value, as early as IND:
    • “If the Secretary approves a request, it shall publish the value of the contract that the critical need antimicrobial developer would be eligible to receive if such developer successfully demonstrates that the drug meets the maximum value of the favored characteristics listed in the application”
    • This means that sponsors will be able to raise funds for clinical trials with a clear view of the commercial value of the product to the US government. The designation derisks the commercial risks, leaving the company to deliver on the technical/scientific front.
  3. The potential value of any given contract is $750m to $1b over 10 years.
  4. $11b is set aside for PASTEUR. $1b of this can be used during a transitional period “… while the Secretary finalizes the subscription contract regulations.” $500M is set aside to strengthen stewardship, especially in rural, tribal, and safety-net hospitals.
  5. Under this subscription, the federal government has prepaid for all of the drug needed by all US federal programs, but not private insurance in the US or any international sales. The bill encourages other governments and payers to design their own subscriptions.
  6. If the drug turns out to be a dud or becomes a blockbuster, the subscriptions cease. 


Wow! When PASTEUR passes, we’ll have all the pieces in place to drive a credible and functional AMR R&D ecosystem: the early R&D push incentives (CARB-XNovo REPAIR, and multiple government level sources), a substantial late R&D push incentive (AMR Action Fund), and now substantial pull incentives with PASTEUR and the NHS Pilot.

The AMR R&D community has been working towards this for 10 years: the PASTEUR ACT levels the economic playing field so that it makes as much sense to pursue a new antimicrobial agent as it does to pursue a new cancer therapy. And this leveling up will only be improved as we (hopefully) see other governments jump into provide their fair share. The UK’s implied estimate of $4b as the value of truly innovative new agent has set the bar at an appropriate level and PASTEUR is saying the US will contribute its G20-proportionate share as well.

But (and this is a key point for the R&D community!), these sums of money will only be made available to products that really shine in some obvious, readily demonstrable way.

“Yet another” won’t cut it  everybody doing antimicrobial R&D needs to take a deep breath and ask if the world will be excited by what they are developing! On the theme of avoiding products that provoke a yawn response, please review the 5 June 2021 newsletter entitled “G7 Health Ministers 3-4 June Communique / Implications For Choosing Wisely.” Please also consider the ways that the various pipeline reviews have evaluated novelty and potential utility — there are some very important lessons here. 

Enough said! Let’s get busy and innovate our way out of the AMR crisis! All best wishes, John & Kevin

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.

Kevin Outterson, JD, Professor of Law, Boston University & Executive Director, CARB-X (these views are personal and do not necessarily reflect the views of CARB-X or any of its funders) @koutterson

=== COPY OF PRESS RELEASE ===
FOR IMMEDIATE RELEASE
Wednesday, June 16, 2021

CONTACTS: 
Olivia Bercow (Bennet) – 202-860-5234
Heidi Reutebuch (Young) – 202-224-5623
Matt Dinkel (Doyle) – 202-557-1285
Nadgey Louis-Charles (Ferguson) – 202-802-0078

Bennet, Young, Doyle, Ferguson Introduce PASTEUR Act to Fight Antimicrobial Resistance
Bipartisan, Bicameral Legislation Would Support Development of Innovative Antibiotics to Treat Resistant Infections and Improve Appropriate Antibiotic Use

Washington, D.C.  – Today, U.S. Senators Michael Bennet (D-Colo.) and Todd Young (R-Ind.) and Representatives Mike Doyle (D-Pa.) and Drew Ferguson (R-Ga.) reintroduced the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act to encourage innovative drug development targeting the most threatening infections, improve the appropriate use of antibiotics, and ensure domestic availability when needed.

“After witnessing the COVID-19 pandemic, it has never been more clear that we need to invest in research to prepare for the next public health crisis,” said Bennet. “Infectious disease experts are already sounding alarms, and they need resources to prepare for the threat that antimicrobial resistance infections pose. With our bipartisan PASTEUR Act, we have the chance to not only learn from the mistakes we have made up to this point, but to invest in tools to better prepare for the future.”

“Americans understand – now more than ever – that we must take every reasonable and responsible measure to prevent future public health crises. Antimicrobial resistance has become a growing crisis in recent years. Market failures have resulted in a lack of needed research and development in this field which is a threat to public health. That’s why I’m proud to reintroduce our Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act to incentivize development of new antibiotics. At the same time, the PASTEUR Act will focus on educating health care providers on how to avoid overuse or misuse of these life-saving medications in order to slow the emergence of antibiotic-resistant pathogens,” said Young.

“Tens of thousands of Americans die each year from antimicrobial-resistant infections,” said Doyle. “Infectious disease experts agree that antimicrobial resistance is an urgent public health threat that requires a comprehensive, effective solution now. The PASTEUR Act will help scientists and researchers bring better antimicrobials to market, and it will help hospitals and doctors ensure these drugs are used properly.”    

“Antimicrobial resistance is a looming public health and national security crisis that may one day be our next pandemic if left unaddressed,” said Ferguson. “Applying the lessons learned from COVID by investing in pandemic preparedness now will save lives later, which is why I am so proud to be a part of this bipartisan, bicameral effort. We must bring together the unique capabilities and resources of the public and private sectors to solve the market failures impeding the development of new lines of antibiotics. The PASTEUR Act accomplishes this and I look forward to working with my partners on this legislation towards its enactment.”

According to the Centers for Disease Control and Prevention’s (CDC) Antibiotic Resistance Threats in the United States report, more than 2.8 million antibiotic-resistant infections occur in the United States each year, and at least 35,000 people die as a result. In March 2015, the U.S. National Action Plan for Combating Antibiotic-Resistant Bacteria directed federal agencies to accelerate a coordinated, full government response to antibiotic resistance and take action to expand the ability of our health care system to prevent, identify, and respond to the infection pandemic threat posed by antimicrobial resistance. Part of this plan was to increase and incent development of innovative antimicrobial drugs to treat resistant infections. Because of severe market failures in the health care system, many of the innovative antibiotic companies doing this work have filed for bankruptcy and stopped producing their critical drugs completely. 

The PASTEUR Act would address this market failure and increase public health preparedness by keeping novel antibiotics on the market and improving appropriate use across the health care system. While current contracts between the government and drug makers base payment on volume, the PASTEUR Act would establish a subscription-style model which would offer antibiotic developers an upfront payment in exchange for access to their antibiotics, encouraging innovation and ensuring our health care system is prepared to treat resistant infections. 

Statements of Support

“Colorado BioScience Association applauds Senator Bennet’s leadership on the PASTEUR Act,” said Jennifer Jones Paton, President and CEO of Colorado BioScience Association. “We appreciate your efforts to create new incentives for investment in this space. The proposed legislation will strengthen the development pipeline for antimicrobial products and accelerate the breakthrough work of Colorado companies focused on drug-resistant infections.”

“The global pandemic is a stark reminder that the nation must prepare for threats to public health—and we must act now on the growing threat of antibiotic resistance. Too many drug companies have already left the field, and the pipeline of new drugs is running dry. This bipartisan bill puts forth an innovative strategy to spur development, and make sure these lifesaving drugs will be available when we need them,” said David Hyun, Director, The Pew Charitable Trusts’ Antibiotic Resistance Project. 

“Antimicrobial resistance (AMR) threatens to unravel the gains of modern medicine, as lifesaving procedures including cancer chemotherapy, transplantation and other surgeries all rely upon the availability of safe and effective antibiotics.  AMR also weakens our preparedness and response to public health emergencies, as we have seen during the current pandemic with outbreaks of antibiotic resistant secondary infections in COVID-19 treatment units. The PASTEUR Act takes critical steps to address the threat AMR poses,” said Barbara Alexander, MD; President, Infectious Diseases Society of America; Professor of Medicine, Professor of Pathology, Duke University School of Medicine.

“Antibiotics are the quiet infrastructure undergirding modern medicine. For cancer patients, the second-leading cause of death is infection. The PASTEUR Act ensures that patients who win the fight against cancer don’t succumb to infections. It uses subscriptions to pay for antibiotics over a decade, based on value, not volume. It is the best solution for the AMR innovation gap, the final missing piece in the US National Action Plan on Combating Antibiotic-Resistant Bacteria, and demonstrates US leadership to keep us safe from the next pandemic,” said Kevin Outterson, Executive Director, CARB-X, Professor of Law & N. Neal Pike Scholar in Health and Disability Law – Boston University.

“The Antimicrobial Innovation Alliance has been working with Congress since 2012 on developing incentives in response to global AMR crisis, the silent pandemic. The PASTEUR Act represents the most thoughtful, balanced and meaningful mechanism to ‘pull’ through life-saving medicines for patients in need and we are eager to work for its implementation,” said Barrett Thornhill, Executive Director of the Antimicrobial Innovation Alliance.

“The PASTEUR Act will strengthen our nation’s preparedness and ability to confront multidrug resistant infections that claim at least 35,000 lives in the US annually.  Physicians and our patients need novel antibiotics and resources to support antibiotic stewardship, and the PASTEUR Act will deliver,” said Amy Beth Kressel, MD, MS, Professor of Clinical Medicine, Infectious Diseases, Indiana University School of Medicine.

“COVID-19 is showing that innovation and collaboration are necessary to strengthen global health security and prevent future crises, but COVID-19 will not be the last pandemic that the world faces. Now more than ever, the PASTEUR Act represents a global gamechanger in preparing for the silent pandemic of AMR. AMR is a shared priority for global leaders, with the G7 this month committing to ensure much-needed sustainable innovation in antimicrobial R&D. The global community welcomes the PASTEUR Act, and I applaud the US’ leadership in encouraging investment in developing sustainable, accessible and affordable treatments for patients. The bold action of the PASTEUR Act today would enable humanity to contain the global challenges of tomorrow, protecting global citizens against drug resistance and preserving modern medicine for all,” said Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance.

The PASTEUR Act would:

  • Establish a subscription model to encourage innovative antimicrobial drug development aimed at treating drug-resistant infections. This model will be fully delinked, meaning that participating developers would not receive income, as a part of their subscription payments, based on volume or quantity of sales.  
  • Subscription contracts would contain terms and conditions including product availability to individuals on a government health insurance plan, supporting appropriate use, and completion of postmarketing studies. These contracts could be valuated between $750 million and $3 billion.
  • Build on existing frameworks to improve usage of the CDC National Healthcare Safety Network, the Emerging Infections Program, and other programs to collect and report on antibiotic use and resistance data.
  • Include transition measures such as smaller subscription contracts to support novel antimicrobial drug developers that need a financial lifeline.

Current funding opportunities (most current list is here):

  • MTEC has announced an RFP seeking proposals focused on diagnostics, prevention of endemic diarrhea, and selected antivirals. Go here for the full RFP and search for “FA2.13” to find the infection-focused topics. White papers are due 17 June 2021.
  • GNA NOW (part of the IMI AMR Accelerator) has an open call to identify a novel mechanism antibacterial to add to its portfolio. The selected project would receive resources equivalent up to several million € (to be defined according to project needs); see also this 11 May 2021 newsletter for details. Expressions of interest are due by 18 June 2021.
  • The International Society for Infectious Diseases (ISID) is collaborating with Pfizer fund projects identifying and addressing AMR in the outpatient setting across low-income countries or under-resourced settings in middle-income countries. A total of $1 million USD is available in funding, and programs can apply for a maximum of $100,000 USD to cover program expenses over three years. Go here for details. The deadline is 18 June 2021!
  • CARB-X recently announced that their existing resources will be reserved to fund their existing portfolio (more than 80 total awards, and counting, as they include contracting from prior rounds). New rounds from CARB-X will occur only after new funding is obtained in 2021.
  • It’s not a funder, but AiCuris’ AiCubator offers incubator support to very early stage projects. Read more about it here.
  • The Global AMR R&D Hub’s dynamic dashboard (link) summarizes the global clinical development pipeline, incentives for AMR R&D, and investors/investments in AMR R&D.
  • In addition to the lists provided by the Global AMR R&D Hub, you might also be interested in my most current lists of R&D incentives (link) and priority pathogens (link).


Upcoming meetings of interest to the AMR community (most current list is here):

  • 20-24 Jun 2021 (Toronto): International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-12). Go here for details.
  • 20-24 Jun 2021 (virtual, various times): World Microbe Forum sponsored by the American Society for Microbiology (ASM) and the Federation of European Microbiological Societies (FEMS). Go here for more details and to register.
  • 24 Jun 2021 (virtual, 9-4p CET): “Promoting Innovative Antibiotic R&D in Switzerland,” an event sponsored by the Swiss National Research Programme “Antimicrobial Resistance” (NRP 72). Go here for details and to register.
  • 24 Jun 2021 (virtual, 09:30 AM – 05:30 PM CEST): Workshop entitled “Advancing Data Technologies to corner AMR.” Sponsored by AMR Insights, you can register here.
  • [NEW] 1 July 2021 (virtual, 10:00-11:00 CEST): GARDP-sponsored webinar entitled “Balancing access to and stewardship of antimicrobials in LMICs.” Moderated by Philip Howard (U Leeds, VP BSAC), you can register here for the event.
  • 5 Jul 2021 (online): Royal Society-sponsored webinar entitled “Advances in antimicrobial innovation.” Go here for details and to register.
  • 9-12 Jul 2021 (virtual): Annual ECCMID meeting (#31)
    • Grants supported by the Bill & Melinda Gates Foundation are available to support participation from persons residing in Low- and Lower-middle income countries! Go here for details. Applications are due 10 June.
  • 26 Jul-30 Jul 2021 (online): Small World Initiative Instructor Training Workshop – training for undergraduate professors in the wet lab techniques, parallel curricula, & pedagogical instruction to engage students in the hunt to find new antibiotic-producing soil microbes. Go here to register.
  • 14-29 Aug 2021 (Marine Biology Laboratory, Woods Hole, MA): Residential course entitled “Molecular Mycology: Current Approaches to Fungal Pathogenesis.” This 2-week intensive training program has run annually for many years and gets outstanding reviews. Go here for details.
  • 24-26 Aug 2021 (virtual, timings not stated but presumably EU-centered): The 5th edition of the annual AMR conference sponsored by the BEAM Alliance, CARB-X, the Novo REPAIR Impact Fund, the IMI Accelerator, and the European Biotechnology Network. The in-person version of this meeting is consistently excellent; the video-based version will have to do for 2021. Go here for details. 
  • 8-11 Oct 2021 (Aberdeen, Scotland): 10th Trends in Medical Mycology. Go here for details.
  • 11-15 Oct 2021 (physical, somewhere in the UK): UK-focused Innovation Mission sponsored by Innovate UK in collaboration with AMR Insights and Oxford innovation. This free event seeks to connect AMR-focused start-ups, SMEs and Multinationals, Academia, Research Institutes, Regional Development Companies and other interested stakeholders in the UK, Europe and other parts of the world. Go here for more details.
  • 16-24 Oct 2021 (Annecy, France): Interdisciplinary Course on Antibiotics and Resistance (ICARe). This is a soup-to-nuts residential course on antibiotics, antibiotic resistance, and antibiotic R&D. The course is very intense, very detailed, and gets rave reviews. Registration is here and is limited to 40 students. Bonus feature: For obvious reasons, the course didn’t happen in 2020! But as a celebration of the course’s 5th year, a webinar version was held on 29 Oct 2020: go here to stream it. 
  • 25-28 Oct 2021 (Stellenbosch, South Africa): The University of Cape Town’s H3D Research Centre will celebrate its 10th anniversary with a symposium covering the Centre’s research on Malaria, TB, Neglected Tropical Diseases, and AMR. Go here to register.
  • 5-8 Nov 2021 (Albuquerque, New Mexico): Biannual meeting of the MSGERC (Mycoses Study Group Education and Research Consortium). Save-the-date announcement is here, details to follow.
  • 6-11 Mar 2022 (Il Ciocco, Tuscany): Gordon Research Conference entitled “New Antibacterial Discovery and Development”. Go here for details, go here for the linked 5-6 Mar Gordon Research Seminar that precedes it.

Dear All,
 
The IDWeek 2024 program committee is again seeking programs on novel antimicrobial agents and novel diagnostics for presentation in pipeline sessions! Here’s what is sought:

  • “Industry partners are invited to submit antimicrobials that are in preclinical stages of development (Phase II and III preferred) or recently approved after January 2024.
  • “The pipeline sessions will include antibacterials, antifungals, and antivirals (excluding COVID-19 and HIV).
  • “The committee also invites companies developing novel diagnostic technologies with a minimum of some preliminary proof of concept data to submit.” 

This is a great opportunity to tell the story of your development project! The deadline to submit is Wednesday, June 26 via the application portal. Any questions should be directed to program@idsociety.org. Please share this email with anyone you think might be interested in applying!
 
In addition, I’ll also note that those with a more general story to tell should look at the BugHub Stage (and the Global BugHub stage). Both BugHub variants seek “presentations that touch on your experience of working in infectious diseases and presentations that ultimately lead to a greater understanding of our diverse field” via a TED Talk-esque speech about your work. The deadline for applications is 26 June, the same as for the pipeline sessions.

I look forward to seeing you there! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.

John’s Top Recurring Meetings

Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers are the AMR Conference and the ASM-ESCMID conference. Hope to see you there!

  • 27-30 April 2024 (Barcelona, Spain): 34th ECCMID, the annual meeting of the European Society for Clinical Microbiology and Infectious Diseases. Go here for details. 
  • 17-20 Sep 2024 (Porto, Portugal): ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. Go here for the meeting’s general website. You can’t register (yet) for the 2024 event, but save the date!
  • 16-20 Oct 2024 (Los Angeles, USA): IDWeek 2024, the annual meeting of the Infectious Diseases Society of America. Save the date! More details to come!
  • 25-26 February 2025 (Basel, Switzerland): The 9th AMR Conference 2025. Go here to register

Upcoming meetings of interest to the AMR community:

  • [NEW]  9 Apr 2024 (virtual, 830a-10a ET): GARDP’s next REVIVE webinar entitled “Progressing a discovery project – Criteria and challenges.” Register here.
  • [NEW] 9 Apr 2024 (virtual, 10a-1130a ET): CDC webinar “Impacts of Antimicrobial Resistance on Cancer Care.” Click here for details and to register.
  • 10-11 Apr 2024 (virtual): Sepsis Alliance AMR Conference, a 2-day conference focused on “Practical technologies to manage sepsis and counteract the expanding challenge of antimicrobial resistance.” Go here for details and to register.
  • 26 Apr 2024 (Barcelona, Spain): ESCMID workshop entitled “Using Data Science and Machine Learning for Infection Science: A Hands-on Introduction.” Click here to register or here for more details. 
  • 27-30 April 2024 (Barcelona, Spain): 34th ECCMID, the annual meeting of the European Society for Clinical Microbiology and Infectious Diseases. See Recurring Meetings list, above.
  • 26-31 May 2024 (Montreal, Canada): EDAR7, the McGill AMR Centre’s 7th edition of their Environmental Dimension of Antimicrobial Resistance conference. Go here for details; final abstract deadline is 21 Dec 2023.
  • 28-29 May 2024 (in person, Uppsala, Sweden): Uppsala Antibiotic Days, a broad-ranging 2-day program hosted by the Uppsala Antibiotic Center. Go here for details and to register.
  • [NEW] 30-31 May 2024 (face-to-face in Rockville, Maryland as well as online, 8.30-5.30p ET on 30 May, 9-2.40p on 31 May): NIAID-sponsored workshop entitled “Towards realizing the promise of adjunctive immune therapy for invasive fungal infections”. The agenda covers host immunity to invasive fungal infections, immune modulators in the context of fungal infections; and strategies for testing immune modulators as adjunctive therapy. Go here for more details and to register.
  • 9-13 June 2024 (in person, Ascona, Switzerland): “New Approaches to Combat Antibiotic-Resistant Bacteria, 2nd Edition” is a Sunday-Thursday residential workshop focused on the deep biology of AMR. Sponsored by NCCR AntiResist (a Swiss National Science Foundation consortium), the scientific program has the feel of a Gordon Conference. Space is limited, so you are encouraged to apply promptly — go here for details.
  • 13-17 June 2024 (Atlanta, Georgia): ASM Microbe, the annual meeting of the American Society for Microbiology. You can’t register yet, but you can go here for general details.
  • 17-20 Sep 2024 (Porto, Portugal): ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. See Recurring Meetings list, above.
  • 16-20 Oct 2024 (Los Angeles, USA): IDWeek 2024, the annual meeting of the Infectious Diseases Society of America. See Recurring Meetings list, above. 
  • 19-27 Oct 2024 (Annecy, France, residential in-person program): ICARe (Interdisciplinary Course on Antibiotics and Resistance). Now in its 8th year, Patrice Courvalin directs the program with the support of an all-star scientific committee and faculty. The resulting soup-to-nuts training covers all aspects of antimicrobials, is very intense, and routinely gets rave reviews! Seating is limited, so mark your calendars now if you are interested. Applications open in March 2024 — go here for more details.
  • 4-5 Dec 2024 (in person, Washington, DC): “Fungal Dx 2024: Fungal Diagnostics in Clinical Practice” is a 2-day in-person workshop organized by ISHAM‘s Fungal Diagnostics Working Group. The program and registration links are available at https://fungaldx.com/; the agenda is comprehensive and features an all-star global list of speakers.

Share

Tragedy of the (Antibiotic) Commons: A true market failure

Dear All, In a 28 Feb 2024 newsletter entitled “How Economists (And Finance Ministers) Think…”, we reviewed an important new paper on the economics of antibiotics from Anthony McDonnell and his colleagues at CGD (Center for Global Development). The paper’s core theme was that the antibiotic market represents a set of market failures which collectively converge

Ready, set, go! AMR appropriations in the US FY2025 budget

Dear All, If you follow US politics, you will know that the USG (US Government) is beginning its appropriations process for FY2025 (Federal Year 2025). In preparation, a letter calling for AMR-related funding has been drafted by the Infectious Diseases Society of America (IDSA), AdvaMedDx, American Society for Microbiology (ASM), Association for Professionals in Infection Control

2024 CARB-X funding rounds: Treatment, Prevention, and Diagnostics

Note: The fabulous ICARe course organized since 2016 by Patrice Courvalin is urgently seeking additional sources of funding. This one-week intensive residential program is the only soup-to-nuts training program in all things AMR on the planet and routinely gets rave reviews for its content as well as the way it creates fruitful collaborations (and job opportunities). If you know of avenues for support for this extraordinary

Scroll to Top